BioStock: PHI’s CEO eyes new business opportunities

In 2021, PHI entered into a partnership with the US-based RegenMed Development Organization with the goal of establishing the company’s HoloMonitor technology as the standard quality control equipment in the growing field of regenerative medicine. The company has also chartered a new course when it comes to marketing strategy, with a sharp increase in sales over the last 4 quarters as a result. BioStock contacted CEO Peter Egelberg to find out more about the rights issue of just over 72 million SEK that is currently underway, and his vision for the future.

Read the full interview with Peter Egelberg at biostock.se:

https://www.biostock.se/en/2022/03/phis-ceo-eyes-new-business-opportunities/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/